We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Dimitrios Kontos
AstraZeneca PLC (AZN.LN) said Monday that the European Commission has granted marketing authorization for its Imfinzi cancer treatment.
The EU has authorized Imfinzi as monotherapy for the treatment of locally-advanced, unresectable non-small-cell lung cancer, AstraZeneca said.
Imfinzi is the only immunotherapy to be approved in this setting, the pharmaceutical company said.
The approval follows the positive opinion on July 27 from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com
(END) Dow Jones Newswires
September 24, 2018 11:42 ET (15:42 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
